Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NorthSea Therapeutics B.V.

NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires
From NorthSea Therapeutics B.V.
Via Business Wire
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
From NorthSea Therapeutics B.V.
Via Business Wire
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
From NorthSea Therapeutics B.V.
Via Business Wire
NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes
From NorthSea Therapeutics B.V.
Via Business Wire
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
From NorthSea Therapeutics B.V.
Via Business Wire
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
From NorthSea Therapeutics B.V.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.